GlassScriptPhysician profile
Vanessa Ibrahim
NPI 1558052910
$1,690.99
in general payments reported to CMS, 2019-2025
11 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $608 · 2024: $651 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $371.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Bard Peripheral Vascular, INC. | $335.90 | 2023-2024 | Lutonix Drug Coated Balloon, Fluency Endovascular Stent Graft |
| Zimmer Biomet Holdings, INC. | $273.48 | 2023-2025 | Ribfix Titan, Ribfix Blu Advantage |
| Urgo Medical North America, LLC | $128.52 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Urgok2 |
| Aroa Biosurgery Incorporated | $126.42 | 2024 | |
| Baxter Healthcare | $113.88 | 2023 | Tisseel |
| Astrazeneca Pharmaceuticals LP | $107.06 | 2023 | Andexxa |
| Organogenesis INC. | $97.07 | 2025 | Puraply Wound Matrix |
| Convatec INC. | $94.90 | 2024 | |
| W. L. Gore & Associates, INC. | $23.24 | 2025 | Gore Viatorr Tips Endoprosthesis With Controlled Expansion |
| Becton, Dickinson and Company | $18.81 | 2025 | Hemosphere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.